Key result
Doxorubicin and cyclophosphamide linked to rare NSTEMI and SVT in a breast cancer patient.
Why the study?
Chemotherapy-induced myocardial infarction is an exceptionally rare but significant complication of cancer treatment.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the rare occurrence of chemotherapy-induced NSTEMI and SVT with aberrancy following doxorubicin and cyclophosphamide treatment, emphasizing the need for vigilant cardiac monitoring.
Chemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment. This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion. This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.
No takes yet. Share an insight, caveat, or question.
Jobir et al. (2026) conducted a case report in Stage IV breast cancer with chemotherapy-induced NSTEMI and SVT (n=1). Doxorubicin and cyclophosphamide was evaluated. A 52-year-old female with breast cancer developed a rare non-ST elevation myocardial infarction and supraventricular tachycardia three days after receiving doxorubicin and cyclophosphamide.
Synapse has enriched 10 related papers. Consider them for comparative context: